NEOGAP Therapeutics AB

🚀 Proud moment at Advanced Therapies Europe! Our COO Andrea Salmén just took the stage to present how Neogap is advancing a novel, personalized T-cell therapyfor late-stage solid tumors. ✨ What sets us apart: Personalized targets: machine-learning–driven neoantigen selection Potent priming: EpiTCer™ beads train T-cells to effectively kill tumor cells Clinical path: ongoing Phase I/IIa in metastatic colorectal cancer, with strong safety data to date We’re pushing the boundaries of precision immunotherapy—developing a scalable cell therapy platform with the potential to transform treatment for patients who today lack effective options. #AdvancedTherapiesEurope #CellTherapy #ImmunoOncology #SolidTumors #Neoantigens #EpiTCer #NeogapTherapeutics

On 5 September, our founder and CSO Hans Grönlund will present Neogap’s personalised cell therapy at the 2nd Annual Workshop of the Center for Cellular Cancer Therapy (C3T), hosted at Karolinska Institutet – a meeting focused on progress in cell-based therapies for solid tumours. The presentation will highlight how our personalised cell therapy has progressed from early concept into a first-in-human trial. We’re proud to see our work included in a forum that brings research closer to clinical application – and to contribute to the shift towards more individualised cancer treatments. #PersonalisedImmunotherapy #CellTherapy #CancerResearch #ImmunoTherapy  

Neogap is heading to Advanced Therapies Europe 2025 in Barcelona, 2–4 September. Our Head of Cell Therapy Development, Kristine Bylund will be there to connect with peers and share perspectives on advancing personalised immunotherapy with Neogap’s proprietary technologies. Looking forward to fruitful discussions in Barcelona! #AdvancedTherapies #ATEurope 2025 #PersonalisedImmunotherapy #CellTherapy #CancerImmunotherapy

We are pleased to welcome Professor Jonas Mattsson to the Board of Directors. His extensive clinical and academic experience in cell therapy will provide valuable insight as Neogap continues to advance its clinical programme. “Neogap is developing a personalised cell therapy that addresses one of the greatest challenges in modern oncology – the ability to selectively target the unique mutations of a tumour. By using a patient’s own T cells and training them to recognise the tumour-specific targets, the therapy creates a targeted treatment with the potential to cure patients who currently have no remaining treatment options. This is particularly relevant in colorectal cancer, a major disease with rising incidence, especially among younger patients. I look forward to contributing to the company’s continued development.” – Professor Jonas Mattsson Read the full press release – link in the comments. #immunotherapy #personalisedimmunotherapy #celltherapy #EIC #EICfund 

On 4 September, our COO Andrea Salmén will take the stage at the Innovation Exchange, a finalist pitch session at Advanced Therapies Europe in Barcelona. She will present Neogap’s approach to personalised immunotherapy for solid tumours. Her presentation will highlight how our cell therapy selectively targets tumour-specific antigens – enabled by our proprietary technologies PIOR® and EpiTCer®. Neogap is one of six companies selected to pitch, a recognition of the innovation behind our method and its potential to reshape cancer immunotherapy. We’re proud to contribute to the global conversation on how cell therapy can become truly personalised – and more effective. Meet Andrea Salmén and Head of cell therapy development, Kristine Bylund at the conference. 📍 4 September | Innovation Exchange 📍 Advanced Therapies Europe, Barcelona #AdvancedTherapies  #ATEurope 2025 #PersonalisedImmunotherapy #CellTherapy #CancerImmunotherapy

Dagens Nyheter uppmärksammar en svensk studie från Karolinska Institutet som visar att fler yngre drabbas av cancer i tarmarna — en tydlig signal om behovet av både starkare prevention och bättre behandlingar när sjukdomen är spridd. Neogap utvecklar en personaliserad T-cellsbehandling där patientens egna T-celler tränas att hitta och eliminera tumörspecifika mål via vår patenterade EpiTCer-teknologi. Vårt initiala fokus är metastaserad kolorektalcancer, och vår fas I/IIa-studie pågår. Vi fortsätter vårt arbete för att korta vägen från innovation till patientnytta. Hela artikeln i kommentarerna. #tarmcancer #kolorektalcancer #immunterapi #precisionsmedicin #kliniskprövning

🚀 We’re proud to announce that Neogap has been selected as one of six finalists to present at the Innovation Exchange during the upcoming Advanced Therapies Europe conference in Barcelona, September 2–4! This is a great recognition of the innovative concept behind our work—and the urgent need for novel, personalized cancer therapies like ours. We’re looking forward to sharing our progress, connecting with global leaders in advanced therapies, and continuing to push the boundaries of what’s possible in cell therapy. 📍 See you in Barcelona! #AdvancedTherapies #CellTherapy #CancerImmunotherapy #InnovationExchange #Neogap #EpiTCer #Biotech #PrecisionMedicine #ATEurope2025 #LifeScience

I en tid där cancer fortfarande skördar miljoner liv varje år har svenska NEOGAP Therapeutics AB tagit sikte på en ny och revolutionerande metod: att med högteknologisk precision träna patientens eget immunförsvar till att känna igen och slå ut cancerceller – och bara dem. Följ med på en resa in i framtidens cancerbehandling, där varje patients terapi skräddarsys ner till minsta molekyl.

🌟 We are very happy to welcome Katarína Bankóová to the team! 🌟 Katarína holds a BSc in Biomedicine from Karolinska Institutet and brings with her a keen interest in immunology and the complex role of the host microbiome in immune processes. She is passionate about advancing research that leverages the body’s own biological systems to combat diseases such as cancer. Her academic background includes studies in immunology, tumor biology, and bioinformatics at KI, the Royal Institute of Technology (KTH), and Stockholm University. She has also gained valuable hands-on laboratory experience in gut immunology at leading institutions including Imperial College London and the University of Oxford. We’re excited to see her apply her previous experience and enthusiasm to the evolving field of personalised immunotherapy.  Welcome aboard, Katarína!

Great to see the strong engagement following Ola Nilsson’s talk at today’s #Neoantigen Summit in Amsterdam. He shared insights into Neogap’s personalised T-cell therapy and how our EpiTCer® technology supports selective expansion of tumour-specific T cells. Thank you to the organisers for a well-curated and insightful event.